IFNG and neoplasm: The amount of tumor-infiltrating CD4+ T cells exhibited little change in both subcutaneous CT-26 and 4T1 tumors after Fe-Bac-HlpA/CD47nb-BLPs + AMF treatment (Supplementary Fig. 37A and S38); however, the percentages of CD8+ T cells (Fig. 8D and S39), effector CD8+ T cells (CD3+CD8+IFN-γ+ cells; Fig. 8E and S40) and B cells (Fig. 8F and S41) significantly increased in the subcutaneous CT-26 tumors in G4 compared with those in G1, none of which were affected in the subcutaneous 4T1 tumors.